ADAR1 Capital Management’s Grace Therapeutics GRCE Stock Holding History

ADAR1 Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-641,988	Closed	-$2.22M	–	350
2025 Q4	$2.22M	Buy	641,988 +291,538	+83%	+$926K	0.16%	96
2025 Q3	$1.04M	Buy	350,450 +173,823	+98%	+$545K	0.1%	99
2025 Q2	$525K	Sell	176,627 -166,885	-49%	-$444K	0.08%	114
2025 Q1	$783K	Sell	343,512 -430,123	-56%	-$1.36M	0.15%	88
2024 Q4	$2.89M	Sell	773,635 -185,936	-19%	-$637K	0.58%	38
2024 Q3	$2.88M	Hold	959,571	–	–	0.47%	40
2024 Q2	$2.8M	Buy	959,571 +742,190	+341%	+$2.24M	0.53%	31
2024 Q1	$745K	Buy	217,381 +182,849	+530%	+$539K	0.17%	71
2023 Q4	$99.8K	Buy	+34,532	New	+$81.8K	0.04%	95

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

ADAR1 Capital Management's GRCE Position: Q1 2026 in Review

ADAR1 Capital Management sold out of Grace Therapeutics (GRCE) in Q1 2026, closing a stake of 641,988 shares — an estimated $2.22M sold.

ADAR1 Capital Management first reported a position in GRCE in Q4 2023 and held it in 9 quarters. The position peaked at $2.89M in Q4 2024. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

ADAR1 Capital Management reported no remaining Grace Therapeutics position as of Q1 2026 after selling out during the quarter.
ADAR1 Capital Management sold 641,988 Grace Therapeutics shares in Q1 2026, an estimated $2.22M.
ADAR1 Capital Management first reported a position in Grace Therapeutics in Q4 2023 and held it in 9 quarters.
ADAR1 Capital Management's Grace Therapeutics position peaked at $2.89M in Q4 2024.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.